Literature DB >> 8041378

Botulinum toxin in the treatment of dystonic tics.

J Jankovic1.   

Abstract

Botulinum toxin (BTX) injections provide effective treatment for a variety of disorders manifested by inappropriate muscle contractions, but its efficacy in the treatment of tics has not been previously studied. Ten male patients 13-53 years of age who were diagnosed with Tourette's syndrome manifested by disabling focal tics were included in this pilot study. Five patients had frequent blinking and blepharospasm, rendering them "blind," and five patients had severe and painful dystonic tics involving their neck muscles. All 10 patients experienced moderate to marked improvement in the intensity and frequency of tics after BTX injections into the involved muscles. Patients in whom premonitory urges preceded their tics noted marked lessening of these sensory symptoms. The benefit lasted 2-20 weeks after injections. There were no serious complications, except for transient ptosis in two and neck pain, stiffness, or weakness in three patients. BTX injections appear to be safe and effective treatment for patients with focal dystonic tics. The treatment ameliorates not only involuntary movements but also the premonitory sensory component associated with some tics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8041378     DOI: 10.1002/mds.870090315

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Effect of local injection of botulinum toxin on sphincter of Oddi cyclic motility in dogs.

Authors:  H J Wang; M Tanaka; H Konomi; H Toma; K Yokohata; P J Pasricha; A N Kalloo
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

2.  Sensory Phenomena in Tourette Syndrome: Their Role in Symptom Formation and Treatment.

Authors:  David C Houghton; Matthew R Capriotti; Christine A Conelea; Douglas W Woods
Journal:  Curr Dev Disord Rep       Date:  2014-12

3.  Paroxysmal Kinesigenic Dyskinesia May Be Misdiagnosed in Co-occurring Gilles de la Tourette Syndrome.

Authors:  Christos Ganos; Niccolo Mencacci; Alice Gardiner; Roberto Erro; Amit Batla; Henry Houlden; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2014-04-10

Review 4.  Sensory aspects of movement disorders.

Authors:  Neepa Patel; Joseph Jankovic; Mark Hallett
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

Review 5.  Tourette syndrome: clinical characteristics and current management strategies.

Authors:  E H Kossoff; H S Singer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Gilles de la Tourette syndrome: symptomatic treatment based on evidence.

Authors:  M M Robertson; J S Stern
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 7.  Pharmacological options for the treatment of Tourette's disorder.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  The management of tics.

Authors:  David Shprecher; Roger Kurlan
Journal:  Mov Disord       Date:  2009-01-15       Impact factor: 10.338

Review 9.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

Review 10.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.